A Novo Nordisk Phase 3 trial found that 37% of adults with metabolic dysfunction-associated steatohepatitis who received once-weekly semaglutide 2.4 milligrams showed improvement in liver fibrosis without worsening steatohepatitis, a disease that causes the body to store excess fat in the liver.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
